Pemetrexed alone or in combination with cisplatin in the treatment of patients with peritoneal mesothelioma (PM): Outcomes of an expanded access program (EAP) in patients with malignant mesothelioma (MM)

J. D. Bloss,Antoinette J. Wozniak,Pasi A. Jänne,Chandra P. Belani,Mary-Louise Keohan,Helen J. Ross,J. Polikoff,David M. Mintzer,L. Bloss,Coleman K. Obasaju

Pemetrexed alone or in combination with cisplatin in the treatment of patients with peritoneal mesothelioma (PM): Outcomes of an expanded access program (EAP) in patients with malignant mesothelioma (MM)

2004

J. D. Bloss
Antoinette J. Wozniak
Pasi A. Jänne
Chandra P. Belani
Mary-Louise Keohan
Helen J. Ross
J. Polikoff
David M. Mintzer
L. Bloss
Coleman K. Obasaju

7198 Background: The improved efficacy of pemetrexed (ALIMTA, Eli Lilly and Co) in combination with cisplatin versus cisplatin alone, in a phase 3 trial of patients with malignant pleural mesotheli...

Keywords:

Pemetrexed
Pathology
Mesothelioma
Peritoneal mesothelioma
Cisplatin
Expanded access
Medicine
Internal medicine
in patient
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations